Clinical Trials Sponsored by Sun Pharmaceutical Industries Ltd

Total 166 results

Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip (FACT LTS & OA)

Osteoarthritis of the Knee or Hip

United States, Bulgaria, Chile, Colombia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Lithuania, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Ukraine, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA1)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, Hungary, Spain, Germany, United Kingdom, Denmark, Lithuania, Romania, Russian Federation, South Africa, Ukraine
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

To Assess the Patients' Ability to Self-Administer Fasinumab (FACT DEVICE)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Sun Pharmaceutical Industries Limited

Recruiting

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Active Psoriatic Arthritis

United States, Australia, Czechia, Estonia, Korea, Republic of, Poland, Slovakia, Spain, Taiwan, Germany, Italy, India, Canada
Sun Pharmaceutical Industries Limited

Recruiting

Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab

Pregnancy Related

United States
Sun Pharmaceutical Industries Limited

Active, not recruiting

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Chronic Plaque Psoriasis | Moderate to Severe Nail Psoriasis

United States, Australia
Sun Pharmaceutical Industries Limited

Active, not recruiting

Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma (NISSO)

Basal Cell Carcinoma

Spain, Germany, Italy, Switzerland
Sun Pharmaceutical Industries Limited

Completed

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

Non-segmental Vitiligo

United States, India
Sun Pharmaceutical Industries Limited

Completed

Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca (Emerald)

Keratoconjunctivitis Sicca

United States
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) (reSURFACE 2)

Plaque Psoriasis
Sun Pharmaceutical Industries Limited

Terminated

Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%

Plaque Psoriasis

United States
Sun Pharmaceutical Industries Limited

Completed

Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis

Blepharoconjunctivitis
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)

Asthma

United States
Sun Pharmaceutical Industries Limited

Terminated

Efficacy and Safety Of Spil's Estradiol Vaginal Tablet

Vaginal Atrophy | Vulvar Atrophy

India
Sun Pharmaceutical Industries Limited

Recruiting

To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis (SOLARES-AD-1)

Dermatitis, Atopic

United States, El Salvador
Sun Pharmaceutical Industries Limited

Recruiting

To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis (SOLARES-PsO-1)

Moderate to Severe Plaque Psoriasis

United States, El Salvador
Sun Pharmaceutical Industries Limited

Recruiting

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Moderate-to-severe Chronic Plaque Psoriasis

United States, Hungary, India, Poland, Slovakia, Spain
Sun Pharmaceutical Industries Limited

Active, not recruiting

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne

Acne Vulgaris

United States
Sun Pharmaceutical Industries Limited

Active, not recruiting

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne

Acne Vulgaris

United States
Sun Pharmaceutical Industries Limited

Completed

Effect of Cequa™ in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Sun Pharmaceutical Industries Limited

Completed

A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

India, Russian Federation
Sun Pharmaceutical Industries Limited

Completed

Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis

Scalp Psoriasis

United States, Australia
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer (STAAR)

Prostate Cancer

United States
Sun Pharmaceutical Industries Limited

Completed

Study to Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery (ISV-305)

Inflammation and Pain Associated With Cataract Surgery

United States
Sun Pharmaceutical Industries Limited

Withdrawn

A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open Angle Glaucoma
Sun Pharmaceutical Industries Limited

Completed

Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery

Cataract
Sun Pharmaceutical Industries Limited

Completed

Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects (ISV-305)

Active, Symptomatic Blepharitis

United States
Sun Pharmaceutical Industries Limited

Completed

Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects

Ocular Inflammation
Sun Pharmaceutical Industries Limited

Withdrawn

A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease (ISV-101)

Dry Eye Disease
Sun Pharmaceutical Industries Limited

Terminated

To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis

Active Rheumatoid Arthritis

Belgium, Netherlands
Sun Pharmaceutical Industries Limited

Terminated

Efficacy and Safety Study of SUNPG1622

Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis

United States, Hungary, Poland, Spain
Sun Pharmaceutical Industries Limited

Completed

ABSORICA in Patients With Severe Recalcitrant Nodular Acne

Acne

United States
Sun Pharmaceutical Industries Limited

Completed

Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

India
University of Florida
Sun Pharmaceutical Industries Ltd

Recruiting

AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Sun Pharmaceutical Industries Limited

Recruiting

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Psoriatic Arthritis

United States, Australia, Estonia, Japan, Poland, Slovakia, Spain, Taiwan, Czechia, Germany, Korea, Republic of
Sun Pharmaceutical Industries Limited

Active, not recruiting

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Active Psoriatic Arthritis

United States, Australia, Czechia, Germany, India, Japan, Korea, Republic of, Poland, Spain
Sun Pharmaceutical Industries Limited

Completed

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Psoriatic Arthritis

United States, Argentina, Hungary, Mexico, Poland, Russian Federation, Spain, Ukraine
Sun Pharmaceutical Industries Limited

Completed

A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis

Psoriasis

United States
Sun Pharmaceutical Industries Limited

Completed

Efficacy and Safety Study of SUNPG1623

Active Psoriatic Arthritis

United States
Sun Pharmaceutical Industries Limited

Completed

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Keratoconjunctivitis Sicca | Dry Eye Disease

United States
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) (reSURFACE 1)

Plaque Psoriasis
Sun Pharmaceutical Industries Limited

Withdrawn

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

Plaque-type Psoriasis
Sun Pharmaceutical Industries Limited

Withdrawn

Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis

Blepharoconjunctivitis
Sun Pharmaceutical Industries Limited

Completed

Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers

Ocular Inflammation
Sun Pharmaceutical Industries Limited

Completed

An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Keratoconjunctivitis Sicca
Sun Pharmaceutical Industries Limited

Completed

2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery (ISV-305)

Inflammation and Pain Associated With Cataract Surgery

United States

Clinical Trials Sponsored by Sun Pharmaceutical Industries Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations